Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts-Reference-Cited by-同舟云学术

Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts

Published:2017-03 Issue: Volume:104 Page:298-310
ISSN:0891-5849
Container-title:Free Radical Biology and Medicine
language:en
Short-container-title:Free Radical Biology and Medicine

Author:

Lee Tsung-Ming,Chang Nen-Chung,Lin Shinn-Zong

Funder

An-Nan Hospital

China Medical University

Ministry of Science and Technology

Publisher

Elsevier BV

Subject

Physiology (medical),Biochemistry

Reference37 articles.

1. SGLT2 inhibition: a novel strategy for diabetes treatment;Chao;Nat. Rev. Drug Discov.,2010

2. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia;Rieg;Am. J. Physiol. Ren. Physiol.,2014

3. Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice;Kashiwagi;PLoS One,2015

4. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1;Balteau;Cardiovasc. Res.,2011

5. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states;Banerjee;Cardiovasc. Res.,2009

Cited by 375 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myocardial fibrosis from the perspective of the extracellular matrix: Mechanisms to clinical impact;Matrix Biology;2024-12

2. Effects of empagliflozin and dapagliflozin on serum humanin, MOTS-c levels, nitrosative stress, and ferroptosis parameters in diabetic patients with heart failure;European Journal of Pharmacology;2024-11

3. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies;Chemico-Biological Interactions;2024-11

4. Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy?;World Journal of Diabetes;2024-09-15

5. Dapagliflozin in Heart Failure: A Comprehensive Meta-analysis on Functional Capacity, Symptoms, and Safety Outcomes;American Journal of Cardiovascular Drugs;2024-09-11